Brian McVeigh

Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY.

Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation.

4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom.

Redpin Therapeutics, Inc. operates as a biotechnological platform which enables targeted regulation of neuronal activity in brain to achieve treatment and control of CNS circuit and other disorders. The company was founded by Elma S. Hawkins, Jeffrey Friedman, Scott Sternson Michael Kaplitt, Sarah Stanley and Jonathan Dordick in 2017 and is headquartered in New York, NY.

4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom.

Genisphere LLC manufactures kits and reagents used for the ultra-sensitive detection of nucleic acids and proteins. Its solutions are primarily based on its proprietary whole transcriptome RNA Amplification processes, miRNA labeling methodologies, and 3DNA Dendrimer Nanotechnology. The firm's combined technologies permit the interrogation and ultra-sensitive detection of a wide range of biomolecules on a variety of detection platforms, including microarrays, flow and bead based assays, ELISAs, lateral flow assays and RNA sequencing. The company was founded in 1997 and is headquartered in Hatfield, PA.

Genisphere LLC manufactures kits and reagents used for the ultra-sensitive detection of nucleic acids and proteins. Its solutions are primarily based on its proprietary whole transcriptome RNA Amplification processes, miRNA labeling methodologies, and 3DNA Dendrimer Nanotechnology. The firm's combined technologies permit the interrogation and ultra-sensitive detection of a wide range of biomolecules on a variety of detection platforms, including microarrays, flow and bead based assays, ELISAs, lateral flow assays and RNA sequencing. The company was founded in 1997 and is headquartered in Hatfield, PA.

Code Biotherapeutics, Inc. is a next-generation gene therapy company based in Greater Philadelphia. The American company is focused on developing targeted non-viral gene therapies to treat serious and life-threatening genetic diseases. The company uses a novel multivalent synthetic DNA delivery platform called 3DNA, which overcomes many of the challenges associated with viral-based gene therapies. Code Biotherapeutics is advancing an internal pipeline focused on select rare disease programs and establishing partnerships to take forward programs in both rare and prevalent diseases. Code Biotherapeutics is supported by top-tier investors that believe in their work to drive discovery programs forward as they aim to deliver on the promise of their proprietary synthetic DNA-based, non-viral genetic medicines delivery platform. The company was founded by Brian P. McVeigh, who has been the CEO since incorporation.

IP Group Plc /Venture Capital/ (IP Group) is a venture capital subsidiary of IP Group Plc founded in 2001. The firm is headquartered in London, United Kingdom.

Genisphere LLC manufactures kits and reagents used for the ultra-sensitive detection of nucleic acids and proteins. Its solutions are primarily based on its proprietary whole transcriptome RNA Amplification processes, miRNA labeling methodologies, and 3DNA Dendrimer Nanotechnology. The firm's combined technologies permit the interrogation and ultra-sensitive detection of a wide range of biomolecules on a variety of detection platforms, including microarrays, flow and bead based assays, ELISAs, lateral flow assays and RNA sequencing. The company was founded in 1997 and is headquartered in Hatfield, PA.

UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania.

4BIO Ventures Management Ltd (4bio Capital Partners) is an independent venture capital firm founded in 2014 by Andrey Kozlov. The firm headquartered in London, United Kingdom.

UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania.

UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania.

UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania.

UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania.

SciNeuro Pharmaceuticals is a Chinese clinical-stage biotechnology company that focuses on developing therapies for neurodegenerative diseases such as Alzheimer's and Parkinson's disease. SciNeuro Pharmaceuticals is based in Shanghai, China, and has corporate and R&D facilities located in both Shanghai and Beijing. SciNeuro has built a portfolio of pipeline programs that address three key disease-driving mechanisms of neurodegeneration. The company is committed to delivering medicines that can make a difference in the lives of patients around the world. The company is an innovation-driven, neuroscience-focused biopharmaceutical company that uses in-house discovery and development to create innovative therapeutics for neurodegenerative and other CNS diseases. The company was founded in 2020 by Min Li, who has been the CEO since then.

UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania.

IP Group Plc /Venture Capital/ (IP Group) is a venture capital subsidiary of IP Group Plc founded in 2001. The firm is headquartered in London, United Kingdom.

UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania.

UPMC Enterprises (UPMC Enterprises) is a venture capital subsidiary of University of Pittsburgh Medical Center founded in 2014. The firm is headquartered in Pittsburgh, Pennsylvania.

IP Group Plc /Venture Capital/ (IP Group) is a venture capital subsidiary of IP Group Plc founded in 2001. The firm is headquartered in London, United Kingdom.